Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Serelaxin in Patients with Acute Heart Failure
Marco Metra, John R. Teerlink, Gad Cotter, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 8, pp. 716-726
Open Access | Times Cited: 226

Showing 1-25 of 226 citing articles:

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 568-574
Open Access | Times Cited: 628
Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
Kevin Damman, Joost C. Beusekamp, Eva M. Boorsma, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 4, pp. 713-722
Open Access | Times Cited: 368
Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology
Wilfried Müllens, Kevin Damman, Jeffrey M. Testani, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 4, pp. 584-603
Open Access | Times Cited: 313
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction
M. Kittleson, Gurusher Panjrath, Kaushik Amancherla, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 18, pp. 1835-1878
Open Access | Times Cited: 232
Highlights in heart failure
Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, et al.
ESC Heart Failure (2019) Vol. 6, Iss. 6, pp. 1105-1127
Open Access | Times Cited: 212
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
P. Christian Schulze, Jürgen Bogoviku, Julian Westphal, et al.
Circulation (2022) Vol. 146, Iss. 4, pp. 289-298
Open Access | Times Cited: 142
Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
Joyce Njoroge, John R. Teerlink
Circulation Research (2021) Vol. 128, Iss. 10, pp. 1468-1486
Open Access | Times Cited: 133
Trial of an Intervention to Improve Acute Heart Failure Outcomes
Douglas S. Lee, Sharon E. Straus, Michael E. Farkouh, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 22-32
Open Access | Times Cited: 96
Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
Hiroyuki Tsutsui, Nancy M. Albert, Andrew J.S. Coats, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 5, pp. 616-631
Closed Access | Times Cited: 66
Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure
Nikola Kozhuharov, Assen Goudev, Dayana Flores, et al.
JAMA (2019) Vol. 322, Iss. 23, pp. 2292-2292
Open Access | Times Cited: 106
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades
Antoine Kimmoun, Koji Takagi, Emmanuel Gall, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 3, pp. 420-431
Open Access | Times Cited: 87
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
Jasper Tromp, Piotr Ponikowski, Afshin Salsali, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 5, pp. 826-834
Open Access | Times Cited: 85
‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor
Amr Abdin, Stefan D. Anker, Javed Butler, et al.
ESC Heart Failure (2021) Vol. 8, Iss. 6, pp. 4444-4453
Open Access | Times Cited: 77
Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
Hiroyuki Tsutsui, Nancy M. Albert, Andrew J.S. Coats, et al.
Journal of Cardiac Failure (2023) Vol. 29, Iss. 5, pp. 787-804
Closed Access | Times Cited: 29
Safety, tolerability and efficacy of up‐titration of guideline‐directed medical therapies for acute heart failure in elderly patients: A sub‐analysis of the STRONG‐HF randomized clinical trial
Mattia Arrigo, Jan Biegus, Ayu Asakage, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 1145-1155
Open Access | Times Cited: 27
Current Spanish emergency department organization and clinical practices in caring for patients with acute heart failure
Òscar Miró, Carolina Sánchez, Víctor Gil, et al.
Emergencias (2024)
Open Access | Times Cited: 14
Endothelial Dysfunction in Heart Failure: What Is Its Role?
Andrea Drera, Luca Rodella, Elisa Brangi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2534-2534
Open Access | Times Cited: 12
Current RNA strategies in treating cardiovascular diseases
Shirley Pei Shan Chia, Jeremy Kah Sheng Pang, Boon-Seng Soh
Molecular Therapy (2024) Vol. 32, Iss. 3, pp. 580-608
Open Access | Times Cited: 8
Acute heart failure – transitioning from symptom-based care to remission
Gad Cotter, Beth A. Davison, Douglas L. Mann, et al.
Journal of Cardiac Failure (2025)
Open Access | Times Cited: 1
Readmission and death in patients admitted with new‐onset versus worsening of chronic heart failure: insights from a nationwide cohort
Jawad H. Butt, Emil Loldrup Fosbøl, Thomas A. Gerds, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 10, pp. 1777-1785
Open Access | Times Cited: 69
Heart failure in the last year: progress and perspective
Daniela Tomasoni, Marianna Adamo, Markus S. Anker, et al.
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3505-3530
Open Access | Times Cited: 68
Acute heart failure: More questions than answers
Daniela Tomasoni, Carlo Lombardi, Marco Sbolli, et al.
Progress in Cardiovascular Diseases (2020) Vol. 63, Iss. 5, pp. 599-606
Closed Access | Times Cited: 65
Worsening renal function in acute heart failure in the context of diuretic response
Johanna E. Emmens, Jozine M. ter Maaten, Yuya Matsue, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 2, pp. 365-374
Open Access | Times Cited: 52
Lung Ultrasound–Guided Emergency Department Management of Acute Heart Failure (BLUSHED-AHF)
Peter S. Pang, Frances M. Russell, Robert R. Ehrman, et al.
JACC Heart Failure (2021) Vol. 9, Iss. 9, pp. 638-648
Open Access | Times Cited: 45
Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure
Petra Verdino, Stacey L. Lee, Fariba N. Cooper, et al.
British Journal of Pharmacology (2023) Vol. 180, Iss. 15, pp. 1965-1980
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top